Profound Medical Q4 2023 GAAP EPS $(0.420) Misses $(0.330) Estimate, Sales $2.000M Beat $1.977M Estimate
Portfolio Pulse from Benzinga Newsdesk
Profound Medical (NASDAQ:PROF) reported Q4 2023 earnings with a GAAP EPS of $(0.420), missing the $(0.330) estimate, but sales of $2.000M exceeded the $1.977M estimate, marking a 53.85% increase from the previous year.
March 07, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Profound Medical reported a Q4 2023 GAAP EPS of $(0.420), missing estimates, but sales of $2.000M exceeded expectations, showing significant year-over-year growth.
While the EPS miss might concern some investors, the sales beat and significant year-over-year growth could offset negative sentiment. The mixed results present a neutral short-term outlook for PROF's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100